Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Molecular heterogeneity drives the clinical behaviour of childhood medulloblastoma

Project Overview

Brain cancer is the most common type of solid cancer in children in Canada, and medulloblastoma is the most common malignant brain cancer of childhood.  Children diagnosed with medulloblastoma are often left with long-term effects from the intensive treatment. Dr. Taylor is studying how different medulloblastomas vary one from another so that we can avoid over‑treating some children (which causes severe complications) and avoid under treating others (which can result in death).

Work from his team has previously shown that medulloblastoma is not really one disease, but in fact a collection of four very different diseases that look the same under the microscope but are clinically and biologically very different. This new classification is being adopted around the world, and has already had great impact on deciding how much therapy to give to children, and in the design of new clinical trials.

For this project, Dr. Taylor and his team aim to identify a way to predict the aggressiveness of these different cancer subtypes. He has gathered an unprecedented collection of tumour samples from 80 cities around the world. He and his team will study how different medulloblastomas vary from one another and how each tumour changes in response to treatment. This important work will help identify which children have high risk cancers requiring the most aggressive treatments, versus those who can receive a gentler treatment regimen.

Principal Investigator

Michael Taylor , The Hospital For Sick Children

Partners and Donors

Canadian Cancer Society

Project Complete

Molecular heterogeneity drives the clinical behaviour of childhood medulloblastoma

  • Grant Type

    Team grants

  • Area of research

    Cancer

  • Disease Area

    Brain Cancer

  • Competition

    Canadian Cancer Society Impact Grants

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,249,880

  • Health Canada Contribution

    $624,940

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co